I'm a Stock Trader

Two names are lagging when the engine needed them leading

The portfolio held its ground today — but two positions are quietly making the case harder to hold.
Scoreboard Update
EXPERIMENT UPDATE — Day 47 System: -0.3% | SPY (same window): +0.0% | Alpha: -0.3% Win rate: 0% (0/15) Open positions: CRNX (day 35, +1.2%), CRNX (day 30, +0.9%), CRNX (day 29, +0.8%), CRNX (day 28, +0.6%), CRNX (day 27, +0.5%), CRNX (day 26, +0.4%), CRNX (day 23, +0.3%), CRNX (day 22, +0.2%), CRNX (day 21, +0.2%), CRNX (day 20, +0.3%), CRNX (day 19, +0.2%), CRNX (day 16, +0.2%), QLYS (day 14, -3.7%), NWL (day 12, +3.8%), CRNX (day 12, +0.1%), CRNX (day 9, -0.0%), CAKE (day 7, -2.4%)

Today's market and our positions

SPY dropped 0.60% today and didn't even flinch at the close — not a panic, just steady, grinding selling that made it hard for anything to feel good. Day 47 of the live experiment. The system sits at -0.3% versus SPY's flat 0.0% over the same window. Alpha: -0.3%. Win rate is still 0/15 on closed trades. That's the honest number, and we're not hiding from it. The portfolio is heavy with CRNX — twelve positions, all laddered in at slightly different prices between $83.93 and $84.99 — plus QLYS, NWL, and CAKE filling out 17 open slots in total. Today was a hold-and-watch session. The tape didn't invite anything else.

What our open trades are doing

CRNX is the story right now, whether we planned it that way or not. The Relative Strength Engine has been laddering into this name for 35 days, and it closed today at $84.95. Every single CRNX position is green or essentially flat — the oldest entry (Day 35, $83.93) is up +1.22% with alpha of +1.71% against today's SPY drop. That's what relative strength is actually supposed to look like: the market sells off and your name doesn't move with it. The Day 9 position ($84.99 entry) is technically down five cents. Call it flat and move on. NWL is doing something quiet and useful in the background. Up 3.76% from the $6.11 entry on Day 12, with alpha of +4.20% against today's session. A small-cap name holding its ground while the broader market leaks. The Relative Strength Engine flagged it for a reason, and so far it's making the case. QLYS is the position that stings. Down 3.70% from the $176.86 entry on Day 14 — and because SPY was essentially flat over that same window, this is pure stock-level underperformance. Alpha of -3.68%. We're watching it closely. It hasn't hit a stop yet, but it isn't doing what a relative strength pick is supposed to do, and that matters. CAKE tells a similar story — down 2.38% from $109.82 on Day 7, alpha of -2.48%, while SPY was actually up slightly over that window. Two names in the book that are lagging when the engine wanted them leading. That's the real tension heading into tomorrow.

Today's closed trades, post-mortem

Nothing closed today. No post-mortem to run. The moment something exits — win or loss — we'll update the scoreboard in full.

What could change by tomorrow's open

The two names commanding the most attention heading into tomorrow are QLYS and CAKE. Both are underperforming on a relative basis, which is precisely what the Relative Strength Engine didn't want to see. If SPY catches a bid and those two don't follow, the case for holding them gets thinner by the hour. CRNX is a different kind of concern — we're carrying heavy concentration in one name across twelve separate positions. If something shifts in the biotech tape or the stock gets hit on news, that isn't just one loss. That's a portfolio event. Twelve positions in the same ticker isn't something to casually wave away. It's a feature of how the engine ladders in, but the concentration risk is real, it's meaningful, and it deserves to be named.

What we're watching tomorrow

Tomorrow morning the engines run fresh scans, and the first question worth asking is whether the Relative Strength Engine keeps adding to CRNX or whether the ladder finally pauses. Right behind that: do QLYS and CAKE give us a reason to stay patient — or a reason to move on? If SPY opens soft again, we'll find out pretty quickly which names in this book actually belong here.

See how the system backtests →

How our rebuilt system performs against the S&P 500 in testing — year by year, with the honest caveats.


Keep exploring